HC Wainwright Analysts Increase Earnings Estimates for TNGX

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Investment analysts at HC Wainwright boosted their Q2 2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, June 30th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.35) per share for the quarter, up from their prior estimate of ($0.37). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.45) EPS, Q2 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.37) EPS.

Tango Therapeutics Stock Up 0.7%

TNGX opened at $5.69 on Wednesday. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02. The business has a fifty day simple moving average of $3.08 and a 200-day simple moving average of $2.57. The firm has a market cap of $616.74 million, a P/E ratio of -4.66 and a beta of 1.63.

Tango Therapeutics (NASDAQ:TNGX) last announced its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 322.67% and a negative return on equity of 62.75%. The firm had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $6.73 million.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas grew its position in Tango Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock valued at $45,000 after acquiring an additional 3,831 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Tango Therapeutics by 29.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company’s stock valued at $65,000 after purchasing an additional 4,813 shares during the period. Deutsche Bank AG boosted its stake in shares of Tango Therapeutics by 24.1% in the fourth quarter. Deutsche Bank AG now owns 36,653 shares of the company’s stock valued at $113,000 after purchasing an additional 7,128 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Tango Therapeutics by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 22,292 shares of the company’s stock valued at $69,000 after purchasing an additional 7,599 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Tango Therapeutics by 9.9% in the first quarter. Bank of New York Mellon Corp now owns 113,233 shares of the company’s stock valued at $155,000 after purchasing an additional 10,213 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.